Publications

  1. Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larre S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeney LA, Colombo R, Briganti A, Babjuk M, Malmstrom PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Prognostic Factors and Risk Groups in T1G3 Non-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guerin: Results of a Retrospective Multicenter Study of 2451 Patients. Eur Urol. 2015 Jan; 67(1):74-82. Epub 2014 Jul 16.
    View PubMed
  2. Joniau S, Briganti A, Gontero P, Gandaglia G, Tosco L, Fieuws S, Tombal B, Marchioro G, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, Van Poppel H, Spahn M, European Multicenter Prostate Cancer Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study. Eur Urol. 2015 Jan; 67(1):157-64. Epub 2014 Jan 25.
    View PubMed
  3. Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, Vizziello D, Sun M, Karakiewicz PI, Menon M, Montorsi F, Briganti A. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol. 2014 Dec 10; 32(35):3939-47. Epub 2014 Sep 22.
    View PubMed
  4. Viers BR, Boorjian SA, Frank I, Tarrell RF, Thapa P, Karnes RJ, Thompson RH, Tollefson MK. Pretreatment Neutrophil-to-Lymphocyte Ratio Is Associated with Advanced Pathologic Tumor Stage and Increased Cancer-specific Mortality Among Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. Eur Urol. 2014 Dec; 66(6):1157-64. Epub 2014 Feb 26.
    View PubMed
  5. Stewart SB, Cheville JC, Sebo TJ, Frank I, Boorjian SA, Thompson RH, Gettman MT, Tollefson MK, Umbriet EC, Psutka SP, Bergstralh EJ, Rangel L, Karnes RJ. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy. Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):332-7. Epub 2014 Aug 26.
    View PubMed
  6. Viers BR, Sukov WR, Gettman MT, Rangel LJ, Bergstralh EJ, Frank I, Tollefson MK, Thompson RH, Boorjian SA, Karnes RJ. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy. Eur Urol. 2014 Dec; 66(6):1116-24. Epub 2014 Jul 19.
    View PubMed
  7. Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM, Feng FY. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol. 2014 Dec; 15(13):1469-80. Epub 2014 Nov 17.
    View PubMed
  8. Kim SP, Gross CP, Smaldone MC, Han LC, Van Houten H, Lotan Y, Svatek RS, Thompson RH, Karnes RJ, Trinh QD, Kutikov A, Shah ND. Perioperative outcomes and hospital reimbursement by type of radical prostatectomy: results from a privately insured patient population. Prostate Cancer Prostatic Dis. 2014 Oct 14.
    View PubMed
  9. Sprung J, Scavonetto F, Yeoh TY, Kramer JM, Karnes RJ, Eisenach JH, Schroeder DR, Weingarten TN. Outcomes after radical prostatectomy for cancer: a comparison between general anesthesia and epidural anesthesia with fentanyl analgesia: a matched cohort study. Anesth Analg. 2014 Oct; 119(4):859-66.
    View PubMed
  10. Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M 3rd, Briganti A. Metastasis-directed Therapy of Regional and Distant Recurrences After Curative Treatment of Prostate Cancer: A Systematic Review of the Literature. Eur Urol. 2014 Sep 17.
    View PubMed
  11. Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Sun M, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol. 2014 Sep; 66(3):479-86. Epub 2013 Dec 12
    View PubMed
  12. Yeoh TY, Scavonetto F, Weingarten TN, Karnes RJ, van Buskirk CM, Hanson AC, Schroeder DR, Sprung J. Perioperative allogeneic nonleukoreduced blood transfusion and prostate cancer outcomes after radical prostatectomy. Transfusion. 2014 Sep; 54(9):2175-81. Epub 2014 Mar 24.
    View PubMed
  13. Karnes RJ, Murphy CR, Bergstralh EJ, DiMonte G, Cheville JC, Lowe VJ, Mynderse LA, Kwon ED. Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Detected by C-Choline Positron Emission Tomography/Computerized Tomography. J Urol. 2014 Aug 20.
    View PubMed
  14. Lee CT, Chang SS, Kamat AM, Amiel G, Beard TL, Fergany A, Karnes RJ, Kurz A, Menon V, Sexton WJ, Slaton JW, Svatek RS, Wilson SS, Techner L, Bihrle R, Steinberg GD, Koch M. Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial. Eur Urol. 2014 Aug; 66(2):265-72. Epub 2014 Feb 26.
    View PubMed
  15. Gakis G, Boorjian SA, Briganti A, Joniau S, Karazanashvili G, Karnes RJ, Mattei A, Shariat SF, Stenzl A, Wirth M, Stief CG. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur Urol. 2014 Aug; 66(2):191-9. Epub 2013 May 22.
    View PubMed
  16. Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. Combined Value of Validated Clinical and Genomic Risk Stratification Tools for Predicting Prostate Cancer Mortality in a High-risk Prostatectomy Cohort. Eur Urol. 2014 Jul 02.
    View PubMed
  17. Scavonetto F, Yeoh TY, Umbreit EC, Weingarten TN, Gettman MT, Frank I, Boorjian SA, Karnes RJ, Schroeder DR, Rangel LJ, Hanson AC, Hofer RE, Sessler DI, Sprung J. Association between neuraxial analgesia, cancer progression, and mortality after radical prostatectomy: a large, retrospective matched cohort study. Br J Anaesth. 2014 Jul; 113 Suppl 1:i95-102. Epub 2013 Dec 16.
    View PubMed
  18. Kim SP, Gross CP, Nguyen PL, Smaldone MC, Shah ND, Karnes RJ, Thompson RH, Han LC, Yu JB, Trinh QD, Ziegenfuss JY, Sun M, Tilburt JC. Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care. 2014 Jul; 52(7):579-85.
    View PubMed
  19. Han LC, Delpe S, Shah ND, Ziegenfuss JY, Tilburt JC, Karnes RJ, Nguyen PL, Gross CP, Yu JB, Trinh QD, Sun M, Ranasinghe WK, Kim SP. Perceptions of radiation oncologists and urologists on sources and type of evidence to inform prostate cancer treatment decisions. Int J Radiat Oncol Biol Phys. 2014 Jun 1; 89(2):277-83. Epub 2014 Mar 27.
    View PubMed
  20. Reynolds JP, Voss JS, Kipp BR, Karnes RJ, Nassar A, Clayton AC, Henry MR, Sebo TJ, Zhang J, Halling KC. Comparison of urine cytology and fluorescence in situ hybridization in upper urothelial tract samples. Cancer Cytopathol. 2014 Jun; 122(6):459-67. Epub 2014 Mar 06.
    View PubMed
  21. Kim SP, Gross CP, Nguyen PY, Smaldone MC, Thompson RH, Shah ND, Kutikov A, Han LC, Karnes RJ, Ziegenfuss JY, Tilburt JC. Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer. Prostate Cancer Prostatic Dis. 2014 Jun; 17(2):163-9. Epub 2014 Feb 25.
    View PubMed
  22. Knoedler JJ, Karnes RJ, Thompson RH, Rangel LJ, Bergstralh EJ, Boorjian SA. The association of tumor volume with mortality following radical prostatectomy. Prostate Cancer Prostatic Dis. 2014 Jun; 17(2):144-8. Epub 2014 Jan 28.
    View PubMed
  23. Clifton MM, Psutka SP, Boorjian SA, Cheville JC, Thapa P, Thompson RH, Tollefson MK, Karnes RJ, Frank I. Cancer-specific mortality following radical cystectomy for bladder cancer with lymph node involvement: impact of pathologic disease features and adjuvant chemotherapy. World J Urol. 2014 May 15.
    View PubMed
  24. Wu Q, Kohli M, Bergen HR 3rd, Cheville JC, Karnes RJ, Cao H, Young CY, Tindall DJ, McNiven MA, Donkena KV. Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth. Mol Cancer Ther. 2014 May; 13(5):1067-77. Epub 2014 Mar 27.
    View PubMed
  25. Kim SP, Karnes RJ, Nguyen PL, Ziegenfuss JY, Thompson RH, Han LC, Shah ND, Smaldone MC, Gross CP, Frank I, Weight CJ, Beebe TJ, Tilburt JC. A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer. BJU Int. 2014 May; 113(5B):E106-11.
  26. Joniau S, Spahn M, Briganti A, Gandaglia G, Tombal B, Tosco L, Marchioro G, Hsu CY, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, van Poppel H, Gontero P, for the European Multicenter Prostate Cancer Pretreatment Tables Predicting Pathologic Stage of Locally Advanced Prostate Cancer. Eur Urol. 2014 Mar 21.
    View PubMed
  27. Zhong J, Ding L, Bohrer LR, Pan Y, Liu P, Zhang J, Sebo TJ, Karnes RJ, Tindall DJ, van Deursen J, Huang H. p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis. Cancer Res. 2014 Mar 15; 74(6):1870-80. Epub 2014 Jan 30.
    View PubMed
  28. Murphy CR, Karnes RJ. Bladder cancer in males: a comprehensive review of urothelial carcinoma of the bladder. Journal Of Mens Health. 2014 Mar; 11(1):18-27.
  29. Tollefson MK, Karnes RJ, Kwon ED, Lohse CM, Rangel LJ, Mynderse LA, Cheville JC, Sebo TJ. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model. Mayo Clin Proc. 2014 Mar; 89(3):308-18. Epub 2014 Jan 31.
    View PubMed
  30. Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, Bianchi M, Boorjian SA, Sun M, Karakiewicz PI, Montorsi F, Briganti A. Predicting survival of patients with node-positive prostate cancer following multimodal treatment. Eur Urol. 2014 Mar; 65(3):554-62. Epub 2013 Sep 27
    View PubMed
  31. Ross AE, Feng FY, Ghadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson DJ, Triche TJ, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes RJ, Schaeffer EM. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis. 2014 Mar; 17(1):64-9. Epub 2013 Oct 22.
    View PubMed
  32. Tollefson MK, Karnes RJ, Rangel L, Carlson R, Boorjian SA. Blood type, lymphadenectomy and blood transfusion predict venous thromboembolic events following radical prostatectomy with pelvic lymphadenectomy. J Urol. 2014 Mar; 191(3):646-51. Epub 2013 Oct 17
    View PubMed
  33. Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE, Bergstralh EJ. Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol. 2014 Jan; 32(1):43.e1-7. Epub 2013 Jun 28.
    View PubMed
  34. Hubanks JM, Boorjian SA, Frank I, Gettman MT, Thompson RH, Rangel LJ, Bergstralh EJ, Karnes RJ. The presence of extracapsular extension is associated with an increased risk of death from prostate cancer after radical prostatectomy for patients with seminal vesicle invasion and negative lymph nodes. UROL. ONCOL. 2014; 32(1):26.e1-7.
  35. Ross AE, Feng FY, Ghadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson DJS, Triche TJ, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes RJ, Schaeffer EM. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer and Prostatic Diseases. 2014; 17(1):64-9.
  36. Kauf TL, Svatek RS, Amiel G, Beard TL, Chang SS, Fergany A, Karnes RJ, Koch M, O'Hara J, Lee CT, Sexton WJ, Slaton JW, Steinberg GD, Wilson SS, Techner L, Martin C, Moreno J, Kamat AM. Alvimopan, a peripherally acting mu-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: Economic analysis of a phase 4 randomized, controlled trial. J Urol. 2014; 191(6):1721-7.
  37. Breau RH, Karnes RJ, Farmer SA, Thapa P, Cagiannos I, Morash C, Frank I. Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis. BJU Int. 2014; 113(6):900-6.
  38. Kauf TL, Svatek RS, Amiel G, Beard TL, Chang SS, Fergany A, Karnes RJ, Koch M, O'Hara J, Lee CT, Sexton WJ, Slaton JW, Steinberg GD, Wilson SS, Techner L, Martinw C, Moreno J, Kamat AM. Alvimopan, a Peripherally Acting Mu-Opioid Receptor Antagonist, Is Associated With Reduced Costs After Radical Cystectomy-Economic Analysis of a Phase 4 Randomized, Controlled Trial. J Urol. 2013 Dec 13.
    View PubMed
  39. Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, Zimmermann B, Sierocinski T, Triche TJ, Kollmeyer T, Ballman KV, Black PC, Klee GG, Jenkins RB. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol. 2013 Dec; 190(6):2047-53. Epub 2013 Jun 11.
    View PubMed
  40. Parker AS, Thiel DD, Bergstralh E, Carlson RE, Rangel LJ, Joseph RW, Diehl N, Karnes RJ. Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):352-6. Epub 2013 Aug 20.
    View PubMed
  41. Weight CJ, Kim SP, Jacobson DJ, McGree ME, Karnes RJ, St Sauver J. Men (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer: results from a prospectively screened population cohort. Urology. 2013 Dec; 82(6):1211-7. Epub 2013 Oct 19.
    View PubMed
  42. Tollefson MK, Boorjian SA, Gettman MT, Rangel LJ, Bergstralh EJ, Karnes RJ. Preoperative estimated glomerular filtration rate predicts overall mortality in patients undergoing radical prostatectomy. Urol Oncol. 2013 Nov; 31(8):1483-8. Epub 2012 May 10.
    View PubMed
  43. Eisenberg MS, Karnes RJ, Kaushik D, Rangel L, Bergstralh EJ, Boorjian SA. Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy. J Urol. 2013 Nov; 190(5):1735-41. Epub 2013 May 29.
    View PubMed
  44. Woodrum DA, Kawashima A, Karnes RJ, Davis BJ, Frank I, Engen DE, Gorny KR, Felmlee JP, Callstrom MR, Mynderse LA. Magnetic resonance imaging-guided cryoablation of recurrent prostate cancer after radical prostatectomy: initial single institution experience. Urology. 2013 Oct; 82(4):870-5. Epub 2013 Aug 01.
    View PubMed
  45. Kim SP, Tilburt JC, Karnes RJ, Ziegenfuss JY, Han LC, Shah ND, Frank I, Smaldone MC, Gross CP, Yu JB, Trinh QD, Sun M, O'Malley RL, Nguyen PL. Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology. 2013 Oct; 82(4):807-12. Epub 2013 Aug 01.
    View PubMed
  46. Abdollah F, Boorjian S, Cozzarini C, Suardi N, Sun M, Fiorino C, di Muzio N, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A. Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification. Eur Urol. 2013 Oct; 64(4):557-64. Epub 2013 Mar 13.
    View PubMed
  47. Kim SP, Shah ND, Weight CJ, Thompson RH, Wang JK, Karnes RJ, Han LC, Ziegenfuss JY, Frank I, Tollefson MK, Boorjian SA. Population-based trends in urinary diversion among patients undergoing radical cystectomy for bladder cancer. BJU Int. 2013 Aug; 112(4):478-84. Epub 2013 Mar 01.
    View PubMed
  48. Linder BJ, Boorjian SA, Umbreit EC, Carlson RE, Rangel LJ, Bergstralh EJ, Karnes RJ. Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high-risk prostate cancer. Int J Urol. 2013 Aug; 20(8):798-805. Epub 2012 Dec 20.
    View PubMed
  49. Joniau S, Tosco L, Briganti A, Vanden Broeck T, Gontero P, Karnes RJ, Spahn M, Van Poppel H, European Multicenter Prostate Cancer Clinical and Translational research group. Results of surgery for high-risk prostate cancer. Curr Opin Urol. 2013 Jul; 23(4):342-8.
    View PubMed
  50. Kim SP, Shah ND, Karnes RJ, Weight CJ, Shippee ND, Han LC, Boorjian SA, Smaldone MC, Frank I, Gettman MT, Tollefson MK, Thompson RH. Hospitalization costs for radical prostatectomy attributable to robotic surgery. Eur Urol. 2013 Jul; 64(1):11-6. Epub 2012 Aug 20.
    View PubMed
  51. Kovtun IV, Cheville JC, Murphy SJ, Johnson SH, Zarei S, Kosari F, Sukov WR, Karnes RJ, Vasmatzis G. Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. Cancer Res. 2013 Jun 1; 73(11):3275-84. Epub 2013 May 21.
    View PubMed
  52. Kim SP, Karnes RJ, Nguyen PL, Ziegenfuss JY, Han LC, Thompson RH, Trinh QD, Sun M, Boorjian SA, Beebe TJ, Tilburt JC. Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a national survey of radiation oncologists and urologists. J Urol. 2013 Jun; 189(6):2092-8. Epub 2012 Dec 03.
    View PubMed
  53. Weight CJ, Kim SP, Jacobson DJ, McGree ME, Boorjian SA, Thompson RH, Leibovich BC, Karnes RJ, St Sauver J. The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol. 2013 Jun; 63(6):1021-7. Epub 2013 Jan 04.
    View PubMed
  54. Tollefson MK, Karnes RJ, Rangel LJ, Bergstralh EJ, Boorjian SA. The impact of clinical stage on prostate cancer survival following radical prostatectomy. J Urol. 2013 May; 189(5):1707-12. Epub 2012 Nov 15.
    View PubMed
  55. Mitchell CR, Lowe VJ, Rangel LJ, Hung JC, Kwon ED, Karnes RJ. Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. J Urol. 2013 Apr; 189(4):1308-13. Epub 2012 Oct 30
    View PubMed
  56. Briganti A, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B, Chun FK, Sun M, Graefen M, Abdollah F, Marchioro G, Frohenberg D, Giona S, Frea B, Karakiewicz PI, Montorsi F, Van Poppel H, Jeffrey Karnes R, European Multicenter Prostate Cancer Clinical Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol. 2013 Apr; 63(4):693-701. Epub 2012 Sep 05.
    View PubMed
  57. Joniau S, Van der Eeckt K, Briganti A, Gontero P, Van Bruwaene S, Jeffrey Karnes R, Spahn M, Van Poppel H, European Multicenter Prostate Cancer Clinical and Translational research Group (EMPaCT). Current role of surgery for high risk prostate cancer. Arch Esp Urol. 2013 Apr; 66(3):259-73, 259-74.
    View PubMed
  58. Kim SP, Boorjian SA, Shah ND, Weight CJ, Tilburt JC, Han LC, Thompson RH, Trinh QD, Sun M, Moriarty JP, Karnes RJ. Disparities in access to hospitals with robotic surgery for patients with prostate cancer undergoing radical prostatectomy. J Urol. 2013 Feb; 189(2):514-20. Epub 2012 Dec 17.
    View PubMed
  59. Gomez CR, Kosari F, Munz JM, Schreiber CA, Knutson GJ, Ida CM, El Khattouti A, Karnes RJ, Cheville JC, Vasmatzis G, Vuk-Pavlovic S. Prognostic value of discs large homolog 7 transcript levels in prostate cancer. PLoS One. 2013; 8(12):e82833. Epub 2013 Dec 09.
    View PubMed
  60. Bruner B, Nehra A, Rangel L, Bailey C, Bergstralh E, Blute M, Karnes RJ. Association of preoperative testosterone levels with biochemical failure in men undergoing radical prostatectomy. Journal of Men's Health. 2013; 10(4):129-33.
  61. Siddique HR, Parray A, Zhong W, Karnes RJ, Bergstralh EJ, Koochekpour S, Rhim JS, Konety BR, Saleem M. BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer. PLoS One. 2013; 8(1):e52993. Epub 2013 Jan 07.
    View PubMed
  62. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, Karnes RJ, Klee G, Davicioni E, Jenkins RB. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One. 2013; 8(6):e66855. Epub 2013 Jun 24.
    View PubMed
  63. Siddique HR, Parray A, Tarapore RS, Wang L, Mukhtar H, Karnes RJ, Deng Y, Konety BR, Saleem M. BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling. PLoS One. 2013; 8(5):e60664. Epub 2013 May 06.
    View PubMed
  64. Mitchell CR, Boorjian SA, Umbreit EC, Rangel LJ, Carlson RE, Karnes RJ. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int. 2012 Dec; 110(11):1709-13. Epub 2012 Aug 30.
    View PubMed
  65. Boorjian SA, Tollefson MK, Thompson RH, Rangel LJ, Bergstralh EJ, Karnes RJ. Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy. J Urol. 2012 Nov; 188(5):1761-6. Epub 2012 Sep 19.
    View PubMed
  66. Kim SP, Boorjian SA, Shah ND, Karnes RJ, Weight CJ, Moriarty JP, Tollefson MK, Shippee ND, Frank I. Contemporary trends of in-hospital complications and mortality for radical cystectomy. BJU Int. 2012 Oct; 110(8):1163-8. Epub 2012 Mar 22.
    View PubMed
  67. Murphy SJ, Cheville JC, Zarei S, Johnson SH, Sikkink RA, Kosari F, Feldman AL, Eckloff BW, Karnes RJ, Vasmatzis G. Mate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer. DNA Res. 2012 Oct; 19(5):395-406. Epub 2012 Sep 18.
    View PubMed
  68. Karnes RJ, Fernandez CA, Shuber AP. A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria. Mayo Clin Proc. 2012 Sep; 87(9):835-42. Epub 2012 Aug 09.
    View PubMed
  69. Weight CJ, Kim SP, Karnes RJ, Bergstralh EJ, Cheville JC, Leibovich BC. A prospective, controlled phase II study of neoadjuvant exisulind therapy before radical prostatectomy: effect on apoptosis. Urology. 2012 Aug; 80(2):484.e17-22. Epub 2012 Apr 13.
    View PubMed
  70. Kosari F, Cheville JC, Ida CM, Karnes RJ, Leontovich AA, Sebo TJ, Erdogan S, Rodriguez E, Murphy SJ, Vasmatzis G. Shared gene expression alterations in prostate cancer and histologically benign prostate from patients with prostate cancer. Am J Pathol. 2012 Jul; 181(1):34-42. Epub 2012 May 26.
    View PubMed
  71. Kim SP, Shah ND, Karnes RJ, Weight CJ, Frank I, Moriarty JP, Han LC, Borah B, Tollefson MK, Boorjian SA. The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. J Urol. 2012 Jun; 187(6):2011-7. Epub 2012 Apr 11.
    View PubMed
  72. Nabhan M, Kim SP, Shah ND, Bagniewski SM, Shi Q, Karnes RJ, Weight CJ, Davis BJ, Kohli M, Tilburt JC. The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc. 2012 Jun; 87(6):540-7.
    View PubMed
  73. Hubanks JM, Umbreit EC, Karnes RJ, Myers RP. Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series. Eur Urol. 2012 May; 61(5):878-84. Epub 2011 Dec 05.
    View PubMed
  74. Chade DC, Eastham J, Graefen M, Hu JC, Karnes RJ, Klotz L, Montorsi F, van Poppel H, Scardino PT, Shariat SF. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol. 2012 May; 61(5):961-71. Epub 2012 Jan 23.
    View PubMed
  75. Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW, Schaeffer EM, Stief C, Zorn KC. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol. 2012 Apr; 61(4):664-75. Epub 2011 Dec 07.
    View PubMed
  76. Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, Marchioro G, Kneitz B, Walz J, Frohneberg D, Bangma CH, Graefen M, Tizzani A, Frea B, Karnes RJ, Montorsi F, Van Poppel H, Spahn M. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol. 2012 Mar; 61(3):584-92. Epub 2011 Dec 02.
    View PubMed
  77. Boorjian SA, Tollefson MK, Rangel LJ, Bergstralh EJ, Karnes RJ. Clinicopathological predictors of systemic progression and prostate cancer mortality in patients with a positive surgical margin at radical prostatectomy. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):56-62. Epub 2011 Aug 02.
    View PubMed
  78. Dimonte G, Bergstralh EJ, Bolander ME, Karnes RJ, Tindall DJ. Use of tumor dynamics to clarify the observed variability among biochemical recurrence nomograms for prostate cancer. Prostate. 2012 Feb; 72(3):280-90. Epub 2011 May 31.
    View PubMed
  79. Schubert M, Joniau S, Gontero P, Kneitz S, Scholz CJ, Kneitz B, Briganti A, Karnes RJ, Tombal B, Walz J, Hsu CY, Marchioro G, Bader P, Bangma C, Frohneberg D, Graefen M, Schroder F, van Cangh P, van Poppel H, Spahn M. The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis. Adv Urol. 2012; 2012:612707. Epub 2012 Jan 31.
    View PubMed
  80. Fernandez CA, Millholland JM, Zwarthoff EC, Feldman AS, Karnes RJ, Shuber AP. A noninvasive multi-analyte diagnostic assay: Combining protein and DNA markers to stratify bladder cancer patients. Open Access Journal of Urology. 2012; 4(1):17-26.
  81. Kim SP, Karnes RJ. An Editorial Response to the USPTF. Prostate cancer screening: The case for patient-centered shared decision-making. Journal of Men's Health. 2012; 9(1):5-8.
  82. Gleeson FC, Clain JE, Karnes RJ, Rajan E, Topazian MD, Wang KK, Levy MJ. Endoscopic-ultrasound-guided tissue sampling facilitates the detection of local recurrence and extra pelvic metastasis in pelvic urologic malignancy. Diagn Ther Endosc. 2012; 2012:219521. Epub 2012 Jun 19.
    View PubMed
  83. Mahapatra S, Young CY, Kohli M, Karnes RJ, Klee EW, Holmes MW, Tindall DJ, Donkena KV. Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells. Evid Based Complement Alternat Med. 2012; 2012:303019. Epub 2012 Feb 22.
    View PubMed
  84. Inman BA, Frank I, Boorjian SA, Akornor JW, Karnes RJ, Leibovich BC, Blute ML, Bergstralh EJ. Dynamic prediction of metastases after radical prostatectomy for prostate cancer. BJU Int. 2011 Dec; 108(11):1762-8. Epub 2011 May 26.
    View PubMed
  85. Mitchell CR, Umbreit EC, Rangel LJ, Bergstralh EJ, Karnes RJ. Does body mass index "dilute" the predictive property of prostate-specific antigen for tumor volume at radical prostatectomy? Urology. 2011 Oct; 78(4):868-72. Epub 2011 Aug 16.
    View PubMed
  86. Mahapatra S, Karnes RJ, Holmes MW, Young CY, Cheville JC, Kohli M, Klee EW, Tindall DJ, Donkena KV. Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer. AAPS J. 2011 Sep; 13(3):365-77. Epub 2011 May 11.
    View PubMed
  87. Siddique HR, Mishra SK, Karnes RJ, Saleem M. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy. Clin Cancer Res. 2011 Aug 15; 17(16):5379-91. Epub 2011 Jun 28.
    View PubMed
  88. Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, Briganti A, Montorsi F, van der Poel HG, Van Poppel H, Joniau S, Godoy G, Hurtado-Coll A, Gleave ME, Dall'Oglio M, Srougi M, Scardino PT, Eastham JA. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol. 2011 Aug; 60(2):205-10. Epub 2011 Mar 21.
    View PubMed
  89. Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011 Jul 1; 117(13):2883-91. Epub 2011 Jan 10.
    View PubMed
  90. Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, Karnes RJ. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011 Jun; 59(6):893-9. Epub 2011 Feb 22.
    View PubMed
  91. Tollefson MK, Gettman MT, Blute ML, Bergstralh EJ, Rangel LJ, Karnes RJ. Serum calcium is not predictive of aggressive prostate cancer after radical prostatectomy. Urology. 2011 May; 77(5):1161-5. Epub 2010 Dec 03.
    View PubMed
  92. Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, Suardi N, Bianchi M, Tutolo M, Salonia A, Di Muzio N, Rigatti P, Montorsi F, Blute M. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol. 2011 May; 59(5):832-40. Epub 2011 Feb 22.
    View PubMed
  93. Tollefson MK, Gettman MT, Karnes RJ, Frank I. Administrative data sets are inaccurate for assessing functional outcomes after radical prostatectomy. J Urol. 2011 May; 185(5):1686-90. Epub 2011 Mar 21.
    View PubMed
  94. Karnes RJ, Cheville JC, Ida CM, Sebo TJ, Nair AA, Tang H, Munz JM, Kosari F, Vasmatzis G. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status. Cancer Res. 2010 Nov 15; 70(22):8994-9002. Epub 2010 Nov 09.
    View PubMed
  95. Tollefson MK, Blute ML, Rangel LJ, Karnes RJ, Frank I. Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy. J Urol. 2010 Sep; 184(3):925-9.
    View PubMed
  96. Karnes RJ, Breau RH, Lightner DJ. Surgery for urethral cancer. Urol Clin North Am. 2010 Aug; 37(3):445-57.
    View PubMed
  97. Breau RH, Karnes RJ, Jacobson DJ, McGree ME, Jacobsen SJ, Nehra A, Lieber MM, St Sauver JL. The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol. 2010 Aug; 184(2):494-9. Epub 2010 Jun 17.
    View PubMed
  98. Tollefson MK, Blute ML, Rangel LJ, Bergstralh EJ, Boorjian SA, Karnes RJ. The effect of Gleason score on the predictive value of prostate-specific antigen doubling time. BJU Int. 2010 May; 105(10):1381-5. Epub 2009 Oct 26.
    View PubMed
  99. Boorjian SA, Karnes RJ, Crispen PL, Carlson RE, Rangel LJ, Bergstralh EJ, Blute ML. The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol. 2010 Mar; 183(3):1003-9. Epub 2010 Jan 21.
    View PubMed
  100. Donkena KV, Karnes RJ, Young CY. Vitamins and prostate cancer risk. Molecules. 2010 Mar; 15(3):1762-83. Epub 2010 Mar 12.
    View PubMed
  101. Umbreit EC, Dozois EJ, Crispen PL, Tollefson MK, Karnes RJ, Blute ML. Radical prostatectomy for prostate cancer after ileal pouch-anal anastomosis offers oncologic control and sustains quality of life. J Am Coll Surg. 2010 Feb; 210(2):232-9. Epub 2009 Dec 03.
    View PubMed
  102. Karnes RJ, Hatano T, Blute ML, Myers RP. Radical prostatectomy for high-risk prostate cancer. Jpn J Clin Oncol. 2010 Jan; 40(1):3-9. Epub 2009 Oct 19.
    View PubMed
  103. Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Blute ML. Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol. 2009 Dec; 182(6):2708-14.
    View PubMed
  104. He M, Vanaja DK, Karnes RJ, Young CY. Epigenetic regulation of Myc on retinoic acid receptor beta and PDLIM4 in RWPE1 cells. Prostate. 2009 Nov 1; 69(15):1643-50.
    View PubMed
  105. McGee SM, Boorjian SA, Karnes RJ. Carcinosarcoma of the prostate replacing the entire lower genitourinary tract. Urology. 2009 Sep; 74(3):540-1. Epub 2009 Jul 08.
    View PubMed
  106. Gong A, He M, Krishna Vanaja D, Yin P, Karnes RJ, Young CY. Phenethyl isothiocyanate inhibits STAT3 activation in prostate cancer cells. Mol Nutr Food Res. 2009 Jul; 53(7):878-86.
    View PubMed
  107. Donovan MJ, Khan FM, Fernandez G, Mesa-Tejada R, Sapir M, Zubek VB, Powell D, Fogarasi S, Vengrenyuk Y, Teverovskiy M, Segal MR, Karnes RJ, Gaffey TA, Busch C, Haggman M, Hlavcak P, Freedland SJ, Vollmer RT, Albertsen P, Costa J, Cordon-Cardo C. Personalized prediction of tumor response and cancer progression on prostate needle biopsy. J Urol. 2009 Jul; 182(1):125-32. Epub 2009 May 17.
    View PubMed
  108. Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, Cantor CR, Young CY. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest. 2009 Jun; 27(5):549-60.
    View PubMed
  109. Chavin G, Sheinin Y, Crispen PL, Boorjian SA, Roth TJ, Rangel L, Blute ML, Sebo TJ, Tindall DJ, Kwon ED, Karnes RJ. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res. 2009 Mar 15; 15(6):2174-80. Epub 2009 Mar 10.
    View PubMed
  110. Gettman MT, Pereira CW, Lipsky K, Wilson T, Arnold JJ, Leibovich BC, Karnes RJ, Dong Y. Use of high fidelity operating room simulation to assess and teach communication, teamwork and laparoscopic skills: initial experience. J Urol. 2009 Mar; 181(3):1289-96. Epub 2009 Jan 18.
    View PubMed
  111. Kipp BR, Tanasescu M, Else TA, Bryant SC, Karnes RJ, Sebo TJ, Halling KC. Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer. J Mol Diagn. 2009 Mar; 11(2):148-54. Epub 2009 Jan 29.
    View PubMed
  112. Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F, Rigatti P, Montorsi F, Blute ML. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, Eur Urol. 2009 Feb; 55(2):261-70. Epub 2008 Oct 1
    View PubMed
  113. Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Sebo TJ, Blute ML. The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy. J Urol. 2009 Jan; 181(1):95-104; discussion 104. Epub 2008 Nov 13.
    View PubMed
  114. Inman BA, Davies JD, Rangel LJ, Bergstralh EJ, Kwon ED, Blute ML, Karnes RJ, Leibovich BC. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. Cancer. 2008 Oct 1; 113(7):1544-51.
    View PubMed
  115. Kipp BR, Tyner HL, Campion MB, Voss JS, Karnes RJ, Sebo TJ, Halling KC, Zhang J. Chromosomal alterations detected by fluorescence in situ hybridization in urothelial carcinoma and rarer histologic variants of bladder cancer. Am J Clin Pathol. 2008 Oct; 130(4):552-9.
    View PubMed
  116. Voss JS, Kipp BR, Krueger AK, Clayton AC, Halling KC, Karnes RJ, Henry MR, Sebo TJ. Changes in specimen preparation method may impact urine cytologic evaluation. Am J Clin Pathol. 2008 Sep; 130(3):428-33.
    View PubMed
  117. Miller J, Karnes RJ. Primary clear-cell adenocarcinoma of the proximal female urethra: case report and review of the literature. Clin Genitourin Cancer. 2008 Sep; 6(2):131-3.
    View PubMed
  118. Cheville JC, Karnes RJ, Therneau TM, Kosari F, Munz JM, Tillmans L, Basal E, Rangel LJ, Bergstralh E, Kovtun IV, Savci-Heijink CD, Klee EW, Vasmatzis G. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol. 2008 Aug 20; 26(24):3930-6.
    View PubMed
  119. Gettman MT, Karnes RJ, Arnold JJ, Klipfel JM, Vierstraete HT, Johnson ME, Johnson DR, Leibovich BC. Urology resident training with an unexpected patient death scenario: experiential learning with high fidelity simulation. J Urol. 2008 Jul; 180(1):283-8; discussion 288. Epub 2008 May 21.
    View PubMed
  120. Boorjian SA, Crispen PL, Carlson RE, Rangel LJ, Karnes RJ, Frank I, Gettman MT. Impact of obesity on clinicopathologic outcomes after robot-assisted laparoscopic prostatectomy. J Endourol. 2008 Jul; 22(7):1471-6.
    View PubMed
  121. Karnes RJ, Blute ML. Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus. Nat Clin Pract Urol. 2008 Jun; 5(6):329-39. Epub 2008 May 13.
    View PubMed
  122. Kipp BR, Halling KC, Campion MB, Wendel AJ, Karnes RJ, Zhang J, Sebo TJ. Assessing the value of reflex fluorescence in situ hybridization testing in the diagnosis of bladder cancer when routine urine cytological examination is equivocal. J Urol. 2008 Apr; 179(4):1296-301; discussion 1301. Epub 2008 Mar 04.
    View PubMed
  123. Thompson RH, Leibovich BC, Karnes RJ, Bergstralh EJ, Blute ML. Radical retropubic prostatectomy in immunosuppressed transplant recipients. J Urol. 2008 Apr; 179(4):1349-52; discussion 1352-3. Epub 2008 Mar 04.
    View PubMed
  124. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008 Apr; 179(4):1354-60; discussion 1360-1. Epub 2008 Mar 04.
    View PubMed
  125. Kosari F, Munz JM, Savci-Heijink CD, Spiro C, Klee EW, Kube DM, Tillmans L, Slezak J, Karnes RJ, Cheville JC, Vasmatzis G. Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res. 2008 Mar 15; 14(6):1734-43.
    View PubMed
  126. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Frank I, Blute ML. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers. BJU Int. 2008 Feb; 101(3):299-304. Epub 2007 Oct 08.
    View PubMed
  127. Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol. 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. Epub 2007 Jul 16.
    View PubMed
  128. Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, Cheville JC, Sebo TJ, Kwon ED. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007 Aug 15; 67(16):7893-900. Epub 2007 Aug 08.
    View PubMed
  129. Blute ML, Boorjian SA, Leibovich BC, Lohse CM, Frank I, Karnes RJ. Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy. J Urol. 2007 Aug; 178(2):440-5; discussion 444. Epub 2007 Jun 11.
    View PubMed
  130. Miller J, Nwokeji C, Cunningham D, Karnes RJ:. Transitional Cell Carcinoma of the Renal Pelvis with Vena Caval Tumor Thrombus. Issues in Urology. October 2006; 18(5).
  131. Karnes RJ, Whelan CM, Kwon ED. Immunotherapy for prostate cancer. Curr Pharm Des. 2006; 12(7):807-17.
    View PubMed
  132. Kramer SA, Rathbun SR, Elkins D, Karnes RJ, Husmann DA. Double-blind placebo controlled study of alpha-adrenergic receptor antagonists (doxazosin) for treatment of voiding dysfunction in the pediatric population. J Urol. 2005 Jun; 173(6):2121-4; discussion 2124.
    View PubMed
  133. Gillett MD, Cheville JC, Karnes RJ, Lohse CM, Kwon ED, Leibovich BC, Zincke H, Blute ML. Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol. 2005 Jun; 173(6):1893-6.
    View PubMed
  134. Kipp BR, Karnes RJ, Brankley SM, Harwood AR, Pankratz VS, Sebo TJ, Blute MM, Lieber MM, Zincke H, Halling KC. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol. 2005 Feb; 173(2):401-4.
    View PubMed
  135. Frank I, Cheville JC, Blute ML, Lohse CM, Karnes RJ, Weaver AL, Sebo TJ, Nehra A, Zincke H. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. Cancer. 2004 Oct 15; 101(8):1803-8.
    View PubMed
  136. Frank I, Cheville JC, Blute ML, Lohse CM, Nehra A, Weaver AL, Karnes RJ, Zincke H. Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy - clinicopathologic features associated with outcome. Cancer. 2003 May 15; 97(10):2425-31.
    View PubMed
  137. Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, Sebo TJ, Cheville JC, Clayton AC, Krajnik KL, Ebert TA, Nelson RE, Burkhardt HM, Ramakumar S, Stewart CS, Pankratz VS, Lieber MM, Blute ML, Zincke H, Seelig SA, Jenkins RB, O'Kane DJ. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol. 2002 May; 167(5):2001-6.
    View PubMed
  138. Karnes RJ, Nehra A. Ventral, subcoronal, and penoscrotal penile approach for semirigid rod penile prostheses. Atlas of the urologic clinics of North America. 2002; 10(2):181-8.
    View PubMed
  139. Karnes RJ, Gettman MT, Anderson PM, Lager DJ, Blute ML. Primitive neuroectodermal tumor (extraskeletal Ewing's sarcoma) of the kidney with vena caval tumor thrombus. J Urol. 2000 Sep; 164(3 Pt 1):772.
    View PubMed